In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

For Biogen, dapirolizumab pegol is part of a push into the inflammatory and immunological diseases area and diversification away from its traditional focus on central nervous system diseases.

global head of Biogen’s biosimilars unit. “With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

The Felix NeuroAI wristband delivers tailored and dynamic electrical stimulation to the ulnar, median, and radial nerves ...